How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 29 Mar | 06 Apr | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 58.5 | 58.5 | 61.4 | 63.2 | 63.2 | 63.2 | +4.6 |
| Healthcare | 32.9 | 32.9 | 31.0 | 28.4 | 28.4 | 28.4 | -4.6 |
| Chemicals | 4.4 | 4.4 | 4.8 | 3.9 | 3.9 | 3.9 | -0.6 |
| Financial Services | 1.4 | 1.4 | 1.2 | 1.2 | 1.2 | 1.2 | -0.1 |
| Metal | · | · | · | 0.8 | 0.8 | 0.8 | 0.0 |
| Banking | · | · | · | 0.5 | 0.5 | 0.5 | 0.0 |
| Capital Goods | 0.9 | 0.9 | 0.8 | · | · | · | -0.1 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 14.25% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| DIVISLAB | Pharma | 8.43% | 10 | 8 | 1 | 6 | 1 | 1/2 | +8.1% |
| APOLLOHOSP | Healthcare | 6.20% | 10 | 5 | 7 | 2 | 2 | 0/2 | +14.5% |
| LAURUSLABS | Pharma | 5.06% | 8 | 9 | 4 | 4 | 1 | 0/2 | +34.0% |
| TORNTPHARM | Pharma | 4.90% | 10 | 8 | 5 | 6 | 1 | 1/2 | +14.6% |
| MAXHEALTH | Healthcare | 4.90% | 7 | 9 | 5 | 4 | 3 | 0/2 | +12.2% |
| AUROPHARMA | Pharma | 4.28% | 9 | 3 | 10 | 6 | 6 | 0/2 | +14.4% |
| DRREDDY | Pharma | 3.98% | 7 | 2 | 5 | 1 | 7 | 0/2 | -0.3% |
| LUPIN | Pharma | 3.53% | 10 | 10 | 10 | 6 | 7 | 1/2 | +4.0% |
| CIPLA | Pharma | 3.42% | 6 | 3 | 5 | 3 | 6 | 0/2 | +13.9% |
| FORTIS | Healthcare | 3.02% | 8 | 8 | 5 | 2 | 3 | 0/2 | +8.9% |
| NEULANDLAB | Healthcare | 3.00% | 10 | 10 | 5 | 10 | 2 | 1/2 | +27.4% |
| ALKEM | Pharma | 2.88% | 9 | 8 | 8 | 10 | 6 | 1/2 | +0.5% |
| COHANCE | Healthcare | 2.65% | 4 | 5 | 4 | 10 | 4 | 0/2 | +13.2% |
| ABBOTINDIA | Pharma | 2.03% | 4 | 9 | — | 8 | 7 | 0/2 | +0.6% |
| MANKIND | Pharma | 1.95% | 10 | 8 | 9 | 5 | 2 | 0/2 | +18.5% |
| ASTERDM | Healthcare | 1.79% | 10 | 4 | 8 | 3 | 1 | 1/2 | +15.1% |
| SAILIFE | Healthcare | 1.63% | 8 | 9 | 6 | 5 | 2 | 0/2 | +20.3% |
| IPCALAB | Pharma | 1.44% | 10 | 6 | 1 | 8 | 4 | 1/2 | +18.3% |
| LINDEINDIA | Chemicals | 1.30% | 7 | 6 | 1 | 5 | 2 | 0/2 | -6.1% |
| BIOCON | Pharma | 1.26% | 6 | 1 | 10 | 5 | 3 | 0/2 | +12.5% |
| PPLPHARMA | Pharma | 1.24% | 6 | 1 | 5 | 4 | 6 | 0/2 | +14.5% |
| GLENMARK | Pharma | 1.23% | 6 | 9 | 10 | 4 | 3 | 0/2 | +1.5% |
| SBILIFE | Financial Services | 1.22% | 3 | — | 2 | 8 | 10 | 0/2 | -8.6% |
| JUBLINGREA | Chemicals | 1.12% | 6 | 3 | 5 | 10 | 5 | 0/2 | +7.1% |
| RAINBOW | Healthcare | 1.05% | 10 | 7 | 2 | 5 | 4 | 1/2 | +15.3% |
| GLAXO | Healthcare | 0.86% | 6 | 7 | 2 | 6 | 7 | 0/2 | +1.2% |
| ZYDUSLIFE | Pharma | 0.76% | 10 | 10 | 10 | 10 | 6 | 1/2 | +23.3% |
| POLYMED | Healthcare | 0.68% | 5 | 6 | 6 | 6 | 5 | 0/2 | +9.3% |
| YESBANK | Banking | 0.51% | 7 | 1 | 5 | 6 | 6 | 0/2 | +20.6% |
| CAPLIPOINT | Pharma | 0.48% | 10 | 9 | 2 | 1 | 4 | 0/2 | +50.2% |
| SYNGENE | Healthcare | 0.41% | 2 | 3 | 6 | 9 | 7 | 0/2 | -0.6% |
Performance · 4.7y
Over the last 4.7 years ₹100 in the fund grew to ₹175 (+75%), vs ₹149 for Nifty 500 (+49%) and ₹134 for Nifty 50 (+34%). Its relative-strength line ended at 131 vs Nifty 50 and 118 vs Nifty 500 — above 100, sustained outperformance.